Subsequent Event (Details) - Subsequent Event - USD ($) $ / shares in Units, $ in Millions	Feb. 19, 2026	Feb. 17, 2026
Subsequent Event [Line Items]
Global development costs shared (as a percent)	40.00%
Astellas Pharma Inc.
Subsequent Event [Line Items]
Global development costs shared (as a percent)	60.00%
Upfront payments	$ 335
Payments received from collaborative arrangements	240
Proceeds from equity investment	75
Milestone payment	20
Maximum future development, regulatory and ex-US sales milestone payments	1,370
Maximum future development, regulatory and sales milestones payments	1,370
Potential amount	$ 1,600
Sale of stock (in shares)	7,239,382
Sale of stock (in USD per share)		$ 10.36
Share price, premium (as a percent)		50.00%
Volume weighted average price (in days)		30 days